91 related articles for article (PubMed ID: 12015581)
1. Amyloid diseases: small drugs lead the attack.
Iversen L
Nature; 2002 May; 417(6886):231-3. PubMed ID: 12015581
[No Abstract] [Full Text] [Related]
2. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
3. Drug targets for amyloidosis.
Kolstoe SE; Wood SP
Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
[TBL] [Abstract][Full Text] [Related]
4. Structure of pentameric human serum amyloid P component.
Emsley J; White HE; O'Hara BP; Oliva G; Srinivasan N; Tickle IJ; Blundell TL; Pepys MB; Wood SP
Nature; 1994 Jan; 367(6461):338-45. PubMed ID: 8114934
[TBL] [Abstract][Full Text] [Related]
5. [At last new light for the treatment of amyloidosis].
Pettersson T
Duodecim; 2003; 119(12):1097-8. PubMed ID: 12868354
[No Abstract] [Full Text] [Related]
6. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.
Hohenester E; Hutchinson WL; Pepys MB; Wood SP
J Mol Biol; 1997 Jun; 269(4):570-8. PubMed ID: 9217261
[TBL] [Abstract][Full Text] [Related]
8. [Amyloidosis].
Mandema E
Verh K Acad Geneeskd Belg; 1988; 50(3):274-91. PubMed ID: 3064482
[No Abstract] [Full Text] [Related]
9. Glycosaminoglycans inhibit neurodegenerative effects of serum amyloid P component in vitro.
Urbányi Z; Forrai E; Sárvári M; Likó I; Illés J; Pázmány T
Neurochem Int; 2005 May; 46(6):471-7. PubMed ID: 15769549
[TBL] [Abstract][Full Text] [Related]
10. An entropically efficient supramolecular inhibition strategy for Shiga toxins.
Kitov PI; Lipinski T; Paszkiewicz E; Solomon D; Sadowska JM; Grant GA; Mulvey GL; Kitova EN; Klassen JS; Armstrong GD; Bundle DR
Angew Chem Int Ed Engl; 2008; 47(4):672-6. PubMed ID: 18098248
[No Abstract] [Full Text] [Related]
11. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.
Pepys MB; Tennent GA; Booth DR; Bellotti V; Lovat LB; Tan SY; Persey MR; Hutchinson WL; Booth SE; Madhoo S; Soutar AK; Hawkins PN; Van Zyl-Smit R; Campistol JM; Fraser PE; Radford SE; Robinson CV; Sunde M; Serpell LC; Blake CC
Ciba Found Symp; 1996; 199():73-81; discussion 81-9. PubMed ID: 8915605
[TBL] [Abstract][Full Text] [Related]
12. [Novel therapeutic approach to amyloidosis: no implications as yet for patients with Alzheimer's disease].
Lemstra AW; Eikelenboom P; Meijer EW; van Gool WA
Ned Tijdschr Geneeskd; 2002 Sep; 146(37):1720-3. PubMed ID: 12357871
[TBL] [Abstract][Full Text] [Related]
13. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis.
Westermark GT; Westermark P
FEBS Lett; 2009 Aug; 583(16):2685-90. PubMed ID: 19393650
[TBL] [Abstract][Full Text] [Related]
14. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.
Aquilina JA; Robinson CV
Biochem J; 2003 Oct; 375(Pt 2):323-8. PubMed ID: 12892563
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological studies of inducible DNA cross-linking agents.
Weng X; Ren L; Weng L; Huang J; Zhu S; Zhou X; Weng L
Angew Chem Int Ed Engl; 2007; 46(42):8020-3. PubMed ID: 17853519
[No Abstract] [Full Text] [Related]
16. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
Gupta S; Chhibber M; Sinha S; Surolia A
J Med Chem; 2007 Nov; 50(23):5589-99. PubMed ID: 17948976
[TBL] [Abstract][Full Text] [Related]
17. [Rheumatoid arthritis and secondary amyloidosis].
Inada S
Ryumachi; 2000 Oct; 40(5):849-56. PubMed ID: 11215164
[No Abstract] [Full Text] [Related]
18. A genetically encoded diazirine photocrosslinker in Escherichia coli.
Tippmann EM; Liu W; Summerer D; Mack AV; Schultz PG
Chembiochem; 2007 Dec; 8(18):2210-4. PubMed ID: 18000916
[No Abstract] [Full Text] [Related]
19. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
Maeda S
Amyloid; 2003 Aug; 10 Suppl 1():17-20. PubMed ID: 14640037
[TBL] [Abstract][Full Text] [Related]
20. Experimental AA amyloidosis in mice is inhibited by treatment with triptolide, a purified traditional Chinese medicine.
Cui D; Hoshii Y; Kawano H; Sugiyama S; Gondo T; Liu Y; Ishihara T
Int Immunopharmacol; 2007 Sep; 7(9):1232-40. PubMed ID: 17630202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
